Top Authors

• Most frequent coverage on FOLD

• 
  Michael Becker (164 followers)

  • Developments for Parkinson's Disease Ignite Investor Enthusiasm (Mon, Nov 16)
  • Treating Parkinson’s Disease - Investment Opportunities and Challenges (Mon, Aug 3)
  • Genzyme's Manufacturing Disruption Highlights Investment Opportunities (Mon, Jul 20)

  More by Michael Becker on FOLD »
• 
  Mike Havrilla (1925 followers)

  • FDA Calendar Updates: Amgen, Amicus, Oncothyreon and Medarex (Tue, Jun 23)
  • Pending Clinical Trial Results: Ten Extreme Trades (Thu, May 14)
  • FDA, Clinical Trial Calendars: Nine 'Cash Plus Catalyst' Trades (Sun, May 10)

  More by Mike Havrilla on FOLD »
• 
  Mark Mitchell (42 followers)

  • Trial Setback Is Welcome News for Genzyme, But Don't Get Too Excited (Tue, Oct 6)
  • Sell Genzyme Near Term Due to Continued Manufacturing Challenges (Thu, Sep 24)

  More by Mark Mitchell on FOLD »

• Most followed authors on FOLD

• 
  Mike Havrilla (1925 followers)

  • FDA Calendar Updates: Amgen, Amicus, Oncothyreon and Medarex (Tue, Jun 23)
  • Pending Clinical Trial Results: Ten Extreme Trades (Thu, May 14)
  • FDA, Clinical Trial Calendars: Nine 'Cash Plus Catalyst' Trades (Sun, May 10)

  More by Mike Havrilla on FOLD »
• 
  Zacks.com (1057 followers)

  • Amicus Therapeutics: Amigal Drug Shows Promise (Tue, Jul 7)

  More by Zacks.com on FOLD »
• 
  M. E. Garza (520 followers)

  • Shares of HGSI Up Big in Anticipation of Clinical Trials Update (Thu, Jul 16)

  More by M. E. Garza on FOLD »

• Newest authors on FOLD

• 
  Mark Mitchell (42 followers)

  • Trial Setback Is Welcome News for Genzyme, But Don't Get Too Excited (Tue, Oct 6)
  • Sell Genzyme Near Term Due to Continued Manufacturing Challenges (Thu, Sep 24)

  More by Mark Mitchell on FOLD »
• 
  M. E. Garza (520 followers)

  • Shares of HGSI Up Big in Anticipation of Clinical Trials Update (Thu, Jul 16)

  More by M. E. Garza on FOLD »
• 
  Michael Becker (164 followers)

  • Developments for Parkinson's Disease Ignite Investor Enthusiasm (Mon, Nov 16)
  • Treating Parkinson’s Disease - Investment Opportunities and Challenges (Mon, Aug 3)
  • Genzyme's Manufacturing Disruption Highlights Investment Opportunities (Mon, Jul 20)

  More by Michael Becker on FOLD »

• Most commented on FOLD

• 
  Michael Becker (164 followers)

  • Developments for Parkinson's Disease Ignite Investor Enthusiasm (Mon, Nov 16)
  • Treating Parkinson’s Disease - Investment Opportunities and Challenges (Mon, Aug 3)
  • Genzyme's Manufacturing Disruption Highlights Investment Opportunities (Mon, Jul 20)

  More by Michael Becker on FOLD »
• 
  Mike Havrilla (1925 followers)

  • FDA Calendar Updates: Amgen, Amicus, Oncothyreon and Medarex (Tue, Jun 23)
  • Pending Clinical Trial Results: Ten Extreme Trades (Thu, May 14)
  • FDA, Clinical Trial Calendars: Nine 'Cash Plus Catalyst' Trades (Sun, May 10)

  More by Mike Havrilla on FOLD »
• 
  Mark Mitchell (42 followers)

  • Trial Setback Is Welcome News for Genzyme, But Don't Get Too Excited (Tue, Oct 6)
  • Sell Genzyme Near Term Due to Continued Manufacturing Challenges (Thu, Sep 24)

  More by Mark Mitchell on FOLD »